The estimated Net Worth of Tao Fu is at least 5.56 百万$ dollars as of 28 October 2021. Mr Fu owns over 10,000 units of Zai Lab stock worth over 1,671,675$ and over the last 9 years he sold ZLAB stock worth over 3,241,729$. In addition, he makes 649,770$ as Chief Strategy Officer at Zai Lab.
Mr has made over 17 trades of the Zai Lab stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ZLAB stock worth 1,050,000$ on 28 October 2021.
The largest trade he's ever made was exercising 20,000 units of Zai Lab stock on 26 March 2021 worth over 378,400$. On average, Mr trades about 5,177 units every 57 days since 2015. As of 28 October 2021 he still owns at least 77,500 units of Zai Lab stock.
You can see the complete history of Mr Fu stock trades at the bottom of the page.
Tao Fu is the Chief Strategy Officer at Zai Lab.
As the Chief Strategy Officer of Zai Lab, the total compensation of Mr Fu at Zai Lab is 649,770$. There are 2 executives at Zai Lab getting paid more, with Dr. Ying Du having the highest compensation of 1,376,036$.
Mr Fu is 49, he's been the Chief Strategy Officer of Zai Lab since . There are 16 older and 5 younger executives at Zai Lab. The oldest executive at Zai Lab Limited is John Diekman, 77, who is the Independent Director.
Tao's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 4560 JINKE ROAD, BLDG 1, 4TH FLOOR, PUDONG, SHANGHAI, F4, 201210.
Over the last 4 years, insiders at Zai Lab have traded over 44,173,112$ worth of Zai Lab stock and bought 19,000 units worth 666,380$ . The most active insiders traders include Ying Du、William Lis、John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of 432,845$. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth 48,750$.
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
Zai Lab executives and other stock owners filed with the SEC include: